Humulin N (Insulin Human (Rdna))

Humulin N is indicated for use as a basal insulin in adults and children with diabetes.

• Long‑acting insulin therapy for Type 1 diabetes mellitus to provide background insulin coverage.
• Basal insulin component in combination regimens for Type 2 diabetes mellitus when diet, exercise, and oral agents are insufficient.
• Adjunct to rapid‑acting insulin analogues for flexible dosing schedules.
• Management of nocturnal hyperglycaemia and fasting glucose levels.
• Use in pregnant women with diabetes when benefits outweigh potential risks, under medical supervision.

• Humulin N contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation of the insulin receptor substrate, initiating the PI3‑K/Akt signaling cascade. This cascade promotes translocation of GLUT‑4 transporters to the cell membrane, increasing glucose uptake, and suppresses hepatic gluconeogenesis, thereby lowering circulating glucose concentrations. The prolonged suspension delays absorption, extending the duration of action to provide basal insulin coverage for up to 24 hours.

Like all insulin products, Humulin N may be associated with adverse reactions that vary in frequency and severity.

Common

• Hypoglycemia, which may manifest as sweating, tremor, dizziness, hunger, or confusion, especially if meals are missed or activity is increased.
• Mild injection‑site reactions such as pain, redness, swelling, or itching that usually resolve without treatment.
• Lipohypertrophy or localized fat atrophy at sites of repeated injections, potentially affecting insulin absorption.
• Transient weight gain due to improved glucose utilization and fluid retention.

Serious

• Severe hypoglycemia leading to loss of consciousness, seizures, or the need for emergency assistance.
• Allergic reactions ranging from urticaria and angio‑edema to anaphylactic shock, requiring immediate medical care.
• Edema or worsening of pre‑existing heart failure, particularly in patients with renal impairment or high sodium intake.

Healthcare providers should evaluate several safety considerations before initiating Humulin N therapy.

• Assess renal and hepatic function, as impairment may prolong insulin action and increase hypoglycemia risk.
• Educate patients on recognizing and treating hypoglycemia, including the use of fast‑acting carbohydrates.
• Rotate injection sites to reduce lipodystrophy and ensure consistent absorption.
• Monitor blood glucose regularly, especially during dose adjustments, illness, or changes in diet and activity.
• Use caution in pregnant or breastfeeding women; benefits must outweigh potential risks.
• Avoid use in patients with known hypersensitivity to human insulin or any excipients.

Humulin N can interact with other medicines, affecting glucose control or insulin activity.

Avoid

• Concurrent use of other insulin products without proper dose adjustment, which may cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms, making detection more difficult.
• High‑dose corticosteroids that increase insulin resistance and may require higher insulin doses.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that can potentiate hypoglycemia.
• Diuretics, especially thiazides, which may raise blood glucose levels.
• ACE inhibitors or ARBs that may enhance insulin sensitivity, potentially lowering glucose further.
• Alcohol consumption, which can cause delayed hypoglycemia.